Overview
MEDCAPTAIN (2041)
Medcaptain Medical Technology Co., Ltd. manufactures integrated perioperative medical devices in China, Europe, Asia, the Middle East, Africa, North America, an...
- Open
- 6.050
- High
- 6.080
- Low
- 5.900
- Prev. Close
- 6.195
- Volume
- 135.90K
- Turnover
- 809.66K
- Avg Price
- 5.958
- Bid/Ask Ratio
- 97.24%
- Amplitude
- 2.91%
- 52wk High
- 10.900
- Volume Ratio
- 0.00
- Turnover Ratio
- 0.03%
- 52wk Low
- 5.850
- HK Mkt Cap
- 2.89B
- Market CapHKD
- 3.25B
- P/ETTM
- 297.13
- P/EDynamic
- 1,753.61
- P/EStatic
- --
- EPSTTM
- 0.0203
- EPSDynamic
- 0.0034
- EPSStatic
- --
- BVPS
- 4.11
- P/B
- 1.47
- HK Shares
- 479.22M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 538.63M
- Min lot size
- 100
- Currency
- HKD
MEDCAPTAIN Analyst Rating
View moreForecast & Rating
Oct 14, 2026- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 0
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 10
Medcaptain staged a late-session recovery after touching a 52-week low of HK$5.85 on 8 November: it eased to HK$6.00 in the morning session, climbed to HK$6.54 in the afternoon, and closed at HK$6.41, up 7.55%, on 515,000 shares and HK$3.26 million turnover, a thin 0.11% turnover rate. The rebound contrasts with the earnings profile: Q2 2026 revenue rose 16.64% year on year to HK$551.9 million, yet net profit fell 88.3% to HK$4.51 million and operating income dropped 78.4% to HK$9.79 million, while Q1 booked a HK$3.52 million net loss; the latest disclosures showed Q3 adjusted EBITA and sales up 30% and 13% respectively, and Morgan Stanley initiated coverage. The stock remains below its MA60 of HK$7.198, down 27.16% year to date and 41.19% below its HK$10.90 52-week high, at a PE of 315.6x and PB of 1.56x. Though a HK$3.45 billion market cap and light turnover leave daily swings easily amplified.
- Nov, 6
Medcaptain (2041.HK) closed at HK$5.995, down 2.68%, after opening flat at HK$6.16 and sliding to a 14:08 low of HK$5.85, a fresh 52-week low, before a small late recovery; volume was only 154,200 shares worth HK$0.91 million at a 0.03% turnover rate, so thin liquidity rather than fresh news drove the tape. Fundamentals cut both ways: Q3 adjusted EBITA rose 30% and sales 13%, and Q2 revenue reached HK$551.9 million, up 16.6% year on year, yet net profit was just HK$4.51 million, down 88.3%, with operating profit off 78.4% — revenue growth has not converted into earnings. Morgan Stanley initiated coverage with an Overweight rating on the platform model, but the shares still sit below the MA20 of HK$6.35 and MA60 of HK$7.24, down 31.9% year to date and 45% below the 52-week high of HK$10.9. A cooling Hong Kong IPO market and rising break-issue rates weigh on the recently listed stock.
- Oct, 26
Medcaptain (02041.HK) traced a dip-and-rebound session: it slid to 5.955 in the morning, rallied to an intraday 6.460 in the afternoon and settled at 6.440 against a 6.290 prior close, up about 2.4%, driven by Q3 adjusted EBITA growth of 30% with sales up 13% and Morgan Stanley's initiation at Overweight. That contrasts with thin profitability, as Q2 revenue of HK$551.9m rose 16.6% year on year but net profit of HK$4.51m fell 88.3%, leaving EPS at HK$0.009 and the net margin at 0.82%. Price position stays weak: down 28.4% year to date, 42.2% below the HK$10.90 52-week high, beneath the MA20 of 6.841 and MA60 of 7.526, and only 5.9% above the 5.95 52-week low. Though cooling Hong Kong IPO demand, soft retail subscription and a reported 52-week low suggest post-listing liquidity pressure lingers.
- Oct, 16
The Shenzhen-based medical device maker (2041.HK) traced a spike-and-fade session: it opened at HK$6.695, tagged HK$7.000 at 09:41 BJ before momentum stalled, ground lower through the afternoon to HK$6.500 at 15:43 BJ and closed at HK$6.580, the bottom of the day's range and roughly 6.0% below the intraday peak. Volume was thin at 82,400 shares worth HK$554,929, with the HK$6.735 average price sitting above the close, pointing to late-session selling pressure. Having listed on the HKEX only on 7 September 2026, the company is under six weeks into trading, so YTD performance, 52-week high/low and moving-average reference points are not yet available; price is instead shaped by a small free float and light turnover. While the very low single-day volume limits how much weight the move carries.
- Oct, 15
MEDCAPTAIN fell 5.44% to HK$6.695 after spiking to HK$7.425 in early trade and sliding through the session, tagging its intraday low of HK$6.695 at 15:57 BJ, close to the HK$6.075 52-week low set on Oct 12. The move tracks a Hong Kong healthcare IPO glut: weekly recaps flagged a 5.27% weekly decline and repeated post-listing lows, while over 10 A-share issuers have postponed Hong Kong listings and several healthcare debutants broke issue price. Fundamentals show a widening gap, as Q2 revenue of HK$551.9mn rose 16.64% yoy but net profit of only HK$4.51mn fell 88.29%, with EPS at HK$0.0090 and operating profit down 78.38%, while Q1 remained a HK$3.52mn loss, leaving PE at 329.6x and PB at 1.63x. The stock is down 23.92% YTD, 38.58% below its HK$10.9 52-week high and under its MA20 of HK$7.388 and MA60 of HK$7.778, with market cap of HK$3.61bn. Revenue growth, though, remains double-digit.
